ES2459496T3 - Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina - Google Patents

Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina Download PDF

Info

Publication number
ES2459496T3
ES2459496T3 ES10805703.5T ES10805703T ES2459496T3 ES 2459496 T3 ES2459496 T3 ES 2459496T3 ES 10805703 T ES10805703 T ES 10805703T ES 2459496 T3 ES2459496 T3 ES 2459496T3
Authority
ES
Spain
Prior art keywords
undecan
diazaspiro
methyl
quinoxalin
ring system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10805703.5T
Other languages
English (en)
Spanish (es)
Inventor
Sangamesh Badiger
Dirk Behnke
Claudia Betschart
Vinod Chaudhari
Simona Cotesta
Jürgen Hans-Hermann HINRICHS
Silvio Ofner
Chetan Pandit
Jürgen Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2459496T3 publication Critical patent/ES2459496T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES10805703.5T 2009-12-21 2010-12-20 Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina Active ES2459496T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2663DE2009 2009-12-21
INDE26632009 2009-12-21
PCT/EP2010/070263 WO2011076747A1 (en) 2009-12-21 2010-12-20 Diaza-spiro[5.5]undecanes as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
ES2459496T3 true ES2459496T3 (es) 2014-05-09

Family

ID=43640117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10805703.5T Active ES2459496T3 (es) 2009-12-21 2010-12-20 Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina

Country Status (9)

Country Link
US (1) US8530648B2 (enExample)
EP (1) EP2516439B1 (enExample)
JP (1) JP2013515033A (enExample)
CN (1) CN102762567A (enExample)
AR (1) AR079553A1 (enExample)
ES (1) ES2459496T3 (enExample)
TW (1) TW201132642A (enExample)
UY (1) UY33125A (enExample)
WO (1) WO2011076747A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US20120165331A1 (en) * 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
CN104220065A (zh) 2012-02-07 2014-12-17 Eolas治疗公司 取代的脯氨酸/哌啶用作食欲素受体拮抗剂
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
EP3099667B1 (en) * 2014-01-27 2017-11-01 Allergan, Inc. Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation
JP2017100951A (ja) * 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
SMT202200323T1 (it) 2016-02-12 2022-09-14 Astrazeneca Ab Piperidine alo-sostituite come modulatori del recettore di oressina
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
JP2019527233A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
CN106831774B (zh) * 2017-02-07 2019-02-01 上海合全药业股份有限公司 一种(6s，7s)-9-叔丁氧羰基-7-(三氟甲基)-2，9-二氮杂螺[5.5]十一烷的合成方法
AU2019215058A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN113348019A (zh) * 2019-01-28 2021-09-03 三得利控股株式会社 食欲素受体拮抗抑制用组合物
JP7545570B2 (ja) 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
CA3217403A1 (en) * 2021-05-03 2022-11-10 Prafulkumar CHOVATIA Orexin receptor agonists and uses thereof
TW202334121A (zh) * 2021-10-27 2023-09-01 美商翰森生物有限責任公司 哌啶基吲哚衍生物、其製備方法及醫藥用途
WO2023081094A1 (en) * 2021-11-04 2023-05-11 University Of Washington Novel spirocyclic compounds as klhdc2 ligands

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JP4496722B2 (ja) * 2002-06-28 2010-07-07 萬有製薬株式会社 新規ベンズイミダゾール誘導体
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2009506061A (ja) * 2005-08-26 2009-02-12 メルク エンド カムパニー インコーポレーテッド ジアザスピロデカンオレキシン受容体拮抗薬
WO2007058322A1 (ja) * 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途

Also Published As

Publication number Publication date
AR079553A1 (es) 2012-02-01
CN102762567A (zh) 2012-10-31
EP2516439B1 (en) 2014-01-22
JP2013515033A (ja) 2013-05-02
US8530648B2 (en) 2013-09-10
WO2011076747A1 (en) 2011-06-30
TW201132642A (en) 2011-10-01
US20120264748A1 (en) 2012-10-18
EP2516439A1 (en) 2012-10-31
UY33125A (es) 2011-07-29

Similar Documents

Publication Publication Date Title
ES2459496T3 (es) Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
US10829501B2 (en) Spiroheptane salicylamides and related compounds as inhibitors of ROCK
ES2460915T3 (es) Piridinas fusionadas con heteroarilo disustituido
US11952381B2 (en) Cardiac sarcomere inhibitors
ES2774945T3 (es) 2,4-dihidroxi-nicotinamidas como agonistas de APJ
EP3134408B1 (en) FACTOR XIa INHIBITORS
AU2013312931B2 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
KR20210013145A (ko) 키나아제 억제제로서 헤테로시클릭 화합물, 헤테로시클릭 화합물을 포함하는 조성물 및 그 사용 방법
US20120165331A1 (en) Di/tri-aza-spiro-C9-C11alkanes
AU2016372048A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
KR20160055190A (ko) 트립토판 하이드록실레이스 억제제로서 스파이로사이클릭 화합물
CA3096732A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
AU2004231087A1 (en) Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
CA2837312A1 (en) Metabotropic glutamate receptor 5 allosteric modulators and methods of use thereof
WO2014146493A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
JP2021521142A (ja) Ｃｒｈｒ２拮抗薬としての縮合環状尿素誘導体
EP4561552A2 (en) Cdk2 inhibitors and methods of using the same
US20120101110A1 (en) Diaza-spiro[5.5]undecanes
KR20230015404A (ko) 무스카린성 아세틸콜린 수용체 m5의 경쟁적 억제제 및 비경쟁적 억제제